Genotype‐Driven Resolution of Panagglutination Over a Decade of Korean Rare Blood Program Case Archives

Suspected HFA alloantibodies frequently reflect clinically significant antigen deficiencies that cannot be resolved by serologic testing alone. Integration of a centralized molecular workflow with a national registry substantially improves diagnostic accuracy and transfusion safety. Expansion of family-based donor identification and systematic rare-phenotype surveillance is recommended to enhance national transfusion preparedness.